Friday, July 10, 2026

pharma · Pulmonary Hypertension Associated with Interstitial Lung Disease · Pulmonary Arterial Hypertension

Insmed Incorporated

Insmed Incorporated clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bridgewater Township, USA HQ
1,666 Employees
EMA registrant Type
Company details
Status
Public
HQ
Bridgewater Township, USA
Employees
1,666
Programs
7
Drugs
18
Patents
0
Intelligence · Clinical Programs

Insmed Incorporated projects

3 ClinicalTrials.gov programs sponsored by Insmed Incorporated.

Insmed Incorporated has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. INS1007-231

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial
  2. INS1009-202

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial
  3. The BiRCh Study

    Insmed Limited

    Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Insmed Incorporated have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.